about
Tuberculosis vaccine types and timingsVaccines for TB: Lessons from the Past Translating into Future PotentialsExploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infectionProspects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?Association of ESAT-6/CFP-10-induced IFN-γ, TNF-α and IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts and community controls in an endemic setting.Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Latent tuberculosis infection: myths, models, and molecular mechanismsThe role of B cells and humoral immunity in Mycobacterium tuberculosis infectionMycobacterium tuberculosis requires the ECF sigma factor SigE to arrest phagosome maturation.Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infectionThe Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosisProtection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.Down regulated lncRNA MEG3 eliminates mycobacteria in macrophages via autophagyEffect of bacillus Calmette-Guérin vaccination on CD4+Foxp3+ T cells during acquired immune response to Mycobacterium tuberculosis infectionNo significant impact of IFN-γ pathway gene variants on tuberculosis susceptibility in a West African populationA multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.microRNAs in mycobacterial disease: friend or foe?Trends in discovery of new drugs for tuberculosis therapy.Newer patents in antimycobacterial therapy.A review of clinical models for the evaluation of human TB vaccines.Vaccine research and development: tuberculosis as a global health threat.Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes.Immunological properties and protective efficacy of a single mycobacterial antigen displayed on polyhydroxybutyrate beads.GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model.Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to Mycobacterium tuberculosis.The never-ending story of the fight against tuberculosis: from Koch's bacillus to global control programs
P2860
Q26862762-413DF1C5-C318-4522-AF9E-B55D6B1FFADDQ26996673-D755DAD9-2A0E-41DE-A5AE-35586C053A16Q27323963-82659155-2B06-4F91-A181-BD5F42CA4B4BQ28083377-3F6D5479-9D73-4422-AA77-2E4993AE02F8Q33900138-9C911493-A079-419F-B457-F032CE520E17Q34146613-65F7D229-6FC3-43F0-8BF2-772FE90A69DAQ34297816-25B2FA47-54C3-4637-B35B-2EE5BBCBF25DQ35039807-B88361D1-6869-475B-9EFA-FA9ECCB67F19Q35288521-2BA1D8B3-5A13-4A7F-87C7-9F010596571EQ35439452-9C0E40A7-8344-4CDE-9002-4FCACFB03C0FQ35774458-9FD5ADBC-CC90-4AAD-9A12-4501FA3A8558Q36145657-8486D400-A995-4385-A846-F46655B51BA0Q36499296-FAC02970-CE53-42D2-9DB4-4A983F748604Q36676017-5FEE8175-17BA-493B-89AB-70F0B128ABA3Q37058498-0595B3E3-E8A1-498E-A8C5-10532C902E53Q37135418-61638B1D-38A3-43A9-87AE-8685F806340DQ38167718-BE9D596A-1346-4C99-AFC7-0738921545EAQ38209327-B1D6981C-DD4B-477B-9EFD-F0B553EC036EQ38235400-CC3CE5EE-F286-4E5B-AC2F-A6F25E80E2CDQ38237221-6924F0E4-FCF2-44D9-9C4C-C9E915FD1BC0Q38510495-00D3ED32-92BB-44F0-A29B-7D257C34990BQ38711772-0CB59F47-4698-4FBE-948B-300F8F49AB84Q40059597-3931C108-97B6-4C68-BA3B-EE40AB6E3570Q41704768-01E597E0-9B74-4D26-AD2A-6DF43D4ABA6AQ46088428-C7EF74CD-4265-4243-94AF-9BF04B350142Q46310148-1B8285B0-D1F8-4178-BB86-EC2721DB6975Q47136561-3899F0C4-25E2-4349-9A78-7AA660767C87Q52641618-A9196F66-2A19-4517-8F2B-3167BFFB8A41Q58548220-9119F828-0637-4E0B-B885-98EAE778BBF2
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Vaccine development for tuberculosis: current progress
@ast
Vaccine development for tuberculosis: current progress
@en
Vaccine development for tuberculosis: current progress
@nl
type
label
Vaccine development for tuberculosis: current progress
@ast
Vaccine development for tuberculosis: current progress
@en
Vaccine development for tuberculosis: current progress
@nl
prefLabel
Vaccine development for tuberculosis: current progress
@ast
Vaccine development for tuberculosis: current progress
@en
Vaccine development for tuberculosis: current progress
@nl
P2860
P1433
P1476
Vaccine development for tuberculosis: current progress
@en
P2093
Ian M. Orme
P2860
P2888
P304
P356
10.1007/S40265-013-0081-8
P407
P577
2013-07-01T00:00:00Z
P6179
1002654900